Streptokinase: From Historical Miracle to Modern Thrombolytic Therapy

Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide, with timely reperfusion therapy dramatically improving survival. Streptokinase (SK) is a bacterial protein first isolated in the 1950s, was the first thrombolytic agent to be widely adopted in clinical practice and continues to be used in resource-limited settings. In a recent observational study, patients who received streptokinase within 6 hours of symptom onset had a 30% relative reduction in 30‑day mortality compared with those who did not receive thrombolysis at all. This stark statistic underscores why a thorough understanding of its pharmacology is essential for clinicians and pharmacists alike.

Introduction and Background

Streptokinase (SK) is a 47.5 kDa protein produced by certain strains of Streptococcus pyogenes. Its discovery in the late 1940s revolutionized acute coronary care, providing the first pharmacologic means to dissolve occlusive thrombi. Prior to SK, reperfusion was limited to surgical interventions such as coronary artery bypass grafting, which were not feasible in many patients due to time constraints, comorbidities, or resource availability.

SK belongs to the class of thrombolytic agents that activate the endogenous fibrinolytic system, specifically by converting plasminogen into plasmin. Unlike tissue plasminogen activator (tPA) derivatives, SK does not possess intrinsic fibrin specificity; it binds plasminogen and triggers a conformational change that generates plasmin, which then degrades fibrin strands in the thrombus. This mechanism renders SK effective in dissolving fibrin‑rich clots but also confers a higher risk of systemic bleeding compared with fibrin‑specific thrombolytics.

Epidemiologically, the use of SK has declined in high‑income countries due to the advent of newer agents with improved safety profiles, yet it remains a mainstay in many low‑ and middle‑income regions. According to the World Health Organization, more than 70% of SK administrations worldwide occur in countries where cost constraints limit access to recombinant thrombolytics.

Mechanism of Action

Binding to Plasminogen

SK binds to circulating plasminogen with high affinity, forming a SK–plasminogen complex. This complex mimics the conformational change that occurs when tissue factor stimulates plasminogen activation, thereby exposing the catalytic site of plasminogen and converting it into active plasmin.

Generation of Plasmin and Fibrin Degradation

Once activated, plasmin cleaves fibrin monomers into soluble degradation products, leading to clot dissolution. Plasmin also activates other fibrinolytic pathways, including the conversion of pro‑urokinase and pro‑tissue plasminogen activator into their active forms, amplifying the fibrinolytic cascade.

Systemic Fibrinolysis and Hemorrhagic Risk

Because SK lacks fibrin specificity, plasmin is generated throughout the circulation, not only at the thrombus site. This systemic activation increases the risk of bleeding in remote tissues, particularly in the gastrointestinal tract and intracranial compartment. The lack of a fibrin‑binding domain also means that SK does not preferentially localize to the thrombus, which can limit its efficacy in large, dense clots.

Clinical Pharmacology

Streptokinase is administered exclusively by intravenous infusion, typically over 30–60 minutes. Because it is a proteinaceous agent, it is not absorbed orally and is rapidly cleared by the kidneys.

Pharmacokinetics

After infusion, the plasma concentration of SK peaks within 15–30 minutes, with a mean half‑life of 5–10 minutes. Distribution is predominantly intravascular, with a volume of distribution approximating 4–6 L. Protein binding is modest (~10–20%), allowing for renal excretion of the majority of the drug. Hepatic metabolism plays a negligible role.

Pharmacodynamics

SK exerts a dose‑dependent effect on clot lysis, with the therapeutic window defined by the balance between fibrinolysis and bleeding. The standard dosing regimen for acute MI is 1–2 million units over 30–60 minutes, depending on patient weight and institutional protocol. In ischemic stroke, dosing is 1 million units over 30 minutes, followed by a maintenance infusion of 1 million units over 2 hours.

Therapeutic Applications

• Acute Myocardial Infarction (AMI) – 1–2 million units IV over 30–60 minutes; effective when administered within 6 hours of symptom onset.
• Acute Ischemic Stroke – 1 million units IV over 30 minutes, followed by 1 million units over 2 hours; recommended within 3 hours of symptom onset (extended to 4.5 hours in selected patients).
• Acute Pulmonary Embolism (PE) – 1–2 million units IV over 30–60 minutes; indicated for massive or submassive PE with hemodynamic compromise.
• Deep Vein Thrombosis (DVT) – 1–2 million units IV over 30–60 minutes; used in patients with extensive clot burden or contraindication to anticoagulation.
• Cardiac Surgery – perioperative use to prevent graft occlusion; dosing varies by institutional protocol.

1. Off‑label uses – Reperfusion in inferior STEMI with contraindication to PCI, thrombolysis in acute limb ischemia, and use in patients with left ventricular thrombus.
2. Pediatric use – Limited evidence; dosing extrapolated from adult data, typically 1–2 million units IV over 30–60 minutes for AMI and 1 million units for stroke.
3. Geriatric considerations – No dosage adjustment required, but increased bleeding risk necessitates careful monitoring.
4. Renal impairment – Clearance is primarily renal; in severe renal dysfunction, dose reduction is advised, and infusion duration may be extended.
5. Pregnancy – Category B; use only if benefits outweigh risks; no teratogenic data but potential for fetal bleeding.

Adverse Effects and Safety

Streptokinase’s systemic plasmin activation predisposes patients to bleeding complications. The most common adverse effects include:

• Bleeding (major bleeding 10–20% in AMI patients, 5–10% in stroke patients).
• Allergic reactions (anaphylaxis 0.5–1%, urticaria 2–3%).
• Fever, chills, and rigors during infusion (20–30%).
• Transient thrombocytopenia (5–10%).

Black Box Warning: Major hemorrhage, including intracranial hemorrhage, is a serious and potentially fatal risk. The risk is heightened in patients with recent surgery, uncontrolled hypertension, or concomitant anticoagulant therapy.

Drug Interactions

Monitoring Parameters

• Baseline and serial hemoglobin/hematocrit.
• Platelet count.
• Coagulation profile (PT/INR, aPTT) if on anticoagulants.
• Blood pressure monitoring (avoid >180/110 mmHg).
• Clinical assessment for signs of bleeding (hematoma, hematuria, melena).

Contraindications

• Active internal bleeding.
• Recent hemorrhagic stroke or intracranial surgery.
• Severe uncontrolled hypertension (SBP > 180 mmHg).
• Known hypersensitivity to streptokinase or streptococcal proteins.
• Recent major surgery or trauma within 7 days.

Clinical Pearls for Practice

• “SK is a bacterial protein, not a human enzyme.” This explains its higher immunogenicity and risk of allergic reactions.
• “No fibrin specificity.” Because SK activates plasminogen systemically, bleeding risk is higher compared to tPA variants.
• “Dose by weight is not required.” Standard dose is fixed (1–2 million units) and is not adjusted for body weight.
• “Rapid infusion is essential.” A 30–60 minute infusion maximizes clot lysis while minimizing systemic exposure.
• “Monitor for anaphylaxis.” Treat promptly with epinephrine, antihistamines, and steroids if signs appear.
• “Use only within therapeutic window.” For AMI, within 6 hours of symptom onset; for stroke, within 3–4.5 hours (or 6 hours in extended criteria).
• “Avoid in patients on anticoagulants without careful risk assessment.” The additive bleeding risk may outweigh benefits.

Comparison Table

Exam-Focused Review

Common question stems:

• “Which thrombolytic agent is derived from streptococcal proteins?”
• “Which agent has the highest risk of anaphylaxis?”
• A 55‑year‑old patient with ST‑segment elevation MI presents 4 hours after symptom onset. Which agent is most cost‑effective and appropriate?
• A patient with a history of recent surgery is being considered for thrombolysis. Which agent would you avoid due to bleeding risk?

Key differentiators students often confuse:

• Fibrin specificity vs. systemic plasminogen activation.
• Half‑life differences between SK, alteplase, tenecteplase, and reteplase.
• Administration routes (bolus vs. infusion).
• Indications for use in acute stroke vs. myocardial infarction.

Must‑know facts:

• Streptokinase is a 47.5 kDa protein produced by Streptococcus pyogenes.
• Standard dosing for AMI is 1–2 million units IV over 30–60 minutes.
• Major bleeding risk is highest with streptokinase compared to recombinant tPA agents.
• Allergic reactions are common; treat with epinephrine, antihistamines, and steroids.
• Use only within the therapeutic window (≤6 h for MI, ≤3–4.5 h for stroke).

Key Takeaways

1. Streptokinase is a bacterial protein that activates plasminogen, leading to systemic fibrinolysis.
2. It lacks fibrin specificity, resulting in a higher risk of systemic bleeding.
3. Standard dosing for AMI is 1–2 million units IV over 30–60 minutes.
4. Therapeutic window: ≤6 h for MI, ≤3–4.5 h for stroke.
5. Allergic reactions are common; monitor for anaphylaxis during infusion.
6. Contraindicated in active bleeding, recent intracranial surgery, uncontrolled hypertension, and known hypersensitivity.
7. Drug interactions with anticoagulants and antiplatelets increase bleeding risk.
8. Streptokinase remains cost‑effective in low‑resource settings despite newer agents.
9. Monitoring includes hemoglobin, platelets, BP, and clinical signs of bleeding.
10. Patient‑specific factors (renal function, pregnancy, age) guide dosing and monitoring.

Always balance the benefits of reperfusion with the potential for bleeding. In resource‑limited settings, streptokinase offers a lifesaving option, but meticulous monitoring and patient selection are paramount to minimize harm.